000			02148 a2200601 4500
005			20250514015123.0
264		0	_c20011204
008			200112s 0 0 eng d
022			_a1524-4539
024	7		_a10.1161/hc4401.100078 _2doi
040			_aNLM _beng _cNLM
100	1		_aKonstam, M A
245	0	0	_aCardiovascular thrombotic events in controlled, clinical trials of rofecoxib. _h[electronic resource]
260			_bCirculation _cNov 2001
300			_a2280-8 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAlzheimer Disease _xdrug therapy
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aCardiovascular Diseases _xepidemiology
650	0	4	_aChronic Disease
650	0	4	_aClinical Trials, Phase II as Topic _xstatistics & numerical data
650	0	4	_aClinical Trials, Phase III as Topic _xstatistics & numerical data
650	0	4	_aClinical Trials, Phase IV as Topic _xstatistics & numerical data
650	0	4	_aComorbidity
650	0	4	_aCyclooxygenase 1
650	0	4	_aCyclooxygenase 2
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aIsoenzymes _xantagonists & inhibitors
650	0	4	_aLactones _xadverse effects
650	0	4	_aLow Back Pain _xdrug therapy
650	0	4	_aMale
650	0	4	_aMembrane Proteins
650	0	4	_aMiddle Aged
650	0	4	_aNaproxen _xadverse effects
650	0	4	_aOsteoarthritis _xdrug therapy
650	0	4	_aProportional Hazards Models
650	0	4	_aProstaglandin-Endoperoxide Synthases
650	0	4	_aRandomized Controlled Trials as Topic _xstatistics & numerical data
650	0	4	_aRisk
650	0	4	_aSulfones
650	0	4	_aThrombosis _xepidemiology
700	1		_aWeir, M R
700	1		_aReicin, A
700	1		_aShapiro, D
700	1		_aSperling, R S
700	1		_aBarr, E
700	1		_aGertz, B J
773	0		_tCirculation _gvol. 104 _gno. 19 _gp. 2280-8
856	4	0	_uhttps://doi.org/10.1161/hc4401.100078 _zAvailable from publisher's website
999			_c11611969 _d11611969